Search CTL/CD8+ T-Cell Epitope Database

Found 5 matching records:

Displaying record number 627

Download this epitope record as JSON.

HXB2 Location	gp160(33-42) gp120(33-42) DNA(6321..6350)	gp160 Epitope Map
Author Location	Env(32-41 LAI)
Epitope	KLWVTVYYGV	Epitope Alignment
Epitope Name	Env32-41
Subtype	B
Species (MHC/HLA)	human(A*02:01)
Immunogen	vaccine
Country	United States
Experimental methods	Chromium-release assay
Keywords	dendritic cells, enhancing activity

Vaccine Details

Notes

• Conserved HLA-A*0201-restricted CTL epitopes in HIV-Env were defined and characterized. In 5 HIV-1-infected subjects, 4 epitopes could bind HLA-A*0201 and elicit CTL responses and 2 of these, KLTPLCVTL and SLLNATDIAV, were found to be processed in vivo.
• Peptide 1, KLWVTVYYGV, was recognized by CTL from 1/5 HIV-1-infected patients.

References

Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.

Displaying record number 58643

Download this epitope record as JSON.

HXB2 Location	gp160(121-129) gp120(121-129) DNA(6585..6611)	gp160 Epitope Map
Author Location	Env(120-128 LAI)
Epitope	KLTPLCVTL	Epitope Alignment
Epitope Name	Env120-128
Subtype	B
Species (MHC/HLA)	human(A*02:01)
Immunogen	vaccine
Country	United States
Experimental methods	Chromium-release assay
Keywords	dendritic cells, enhancing activity, novel epitope

Vaccine Details

Notes

• Conserved HLA-A*0201-restricted CTL epitopes in HIV-Env were defined and characterized. In 5 HIV-1-infected subjects, 4 epitopes could bind HLA-A*0201 and elicit CTL responses and 2 of these, KLTPLCVTL and SLLNATDIAV, were found to be processed in vivo.
• Peptide 3, KLTPLCVTL, was recognized by CTL from 3/5 HIV-1-infected patients. This epitope, Env120, is also processed endogenously before presentation.

References

Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.

Displaying record number 58646

Download this epitope record as JSON.

HXB2 Location	gp160(813-822) gp41(302-311) DNA(8661..8690)	gp160 Epitope Map
Author Location	Env(814-823 LAI)
Epitope	SLLNATDIAV	Epitope Alignment
		Show epitope variants
Epitope Name	Env814-823
Subtype	B
Species (MHC/HLA)	human(A*02:01)
Immunogen	vaccine
Country	United States
Experimental methods	Chromium-release assay
Keywords	dendritic cells, enhancing activity, optimal epitope, novel epitope

Vaccine Details

Notes

• Conserved HLA-A*0201-restricted CTL epitopes in HIV-Env were defined and characterized. In 5 HIV-1-infected subjects, 4 epitopes could bind HLA-A*0201 and elicit CTL responses and 2 of these, KLTPLCVTL and SLLNATDIAV, were found to be processed in vivo.
• 10-mer peptide 8, SLLNATDIAV (Env814), was recognized by CTL from 3/5 HIV-1-infected patients. Fine-mapping showed that the decamer SLLNATDIAV is recognized optimally by some HLA-A*0201-CTL (while others recognize the overlapping nonamer, LLNATDIAV). This epitope, Env814, is also processed endogenously before presentation.

References

Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.

Displaying record number 58645

Download this epitope record as JSON.

HXB2 Location	gp160(814-822) gp41(303-311) DNA(8664..8690)	gp160 Epitope Map
Author Location	Env(815-823 LAI)
Epitope	LLNATDIAV	Epitope Alignment
Epitope Name	Env815-823
Subtype	B
Species (MHC/HLA)	human(A*02:01)
Immunogen	vaccine
Country	United States
Experimental methods	Chromium-release assay
Keywords	dendritic cells, enhancing activity, optimal epitope, novel epitope

Vaccine Details

Notes

• Conserved HLA-A*0201-restricted CTL epitopes in HIV-Env were defined and characterized. In 5 HIV-1-infected subjects, 4 epitopes could bind HLA-A*0201 and elicit CTL responses and 2 of these, KLTPLCVTL and SLLNATDIAV, were found to be processed in vivo.
• 9-mer peptide 9, LLNATDIAV, was recognized by CTL from 2/5 HIV-1-infected patients. Fine-mapping showed that the nonamer LLNATDIAV is recognized optimally by some HLA-A*0201-CTL (while others recognize the overlapping decamer, SLLNATDIAV).

References

Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.

Displaying record number 58644

Download this epitope record as JSON.

HXB2 Location	gp160(828-836) gp41(317-325) DNA(8706..8732)	gp160 Epitope Map
Author Location	Env(829-837 LAI)
Epitope	RVIEVLQRA	Epitope Alignment
Epitope Name	Env829-837
Subtype	B
Species (MHC/HLA)	human(A*02:01)
Immunogen	vaccine
Country	United States
Experimental methods	Chromium-release assay
Keywords	dendritic cells, enhancing activity

Vaccine Details

Notes

• Conserved HLA-A*0201-restricted CTL epitopes in HIV-Env were defined and characterized. In 5 HIV-1-infected subjects, 4 epitopes could bind HLA-A*0201 and elicit CTL responses and 2 of these, KLTPLCVTL and SLLNATDIAV, were found to be processed in vivo.
• Peptide 11, RVIEVLQRA, was recognized weakly by CTL from 1/5 HIV-1-infected patients.

References

Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.